{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:57:26Z","timestamp":1780761446510,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K07663"],"award-info":[{"award-number":["21K07663"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K10776"],"award-info":[{"award-number":["24K10776"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shiratori Pharmaceuticals","award":["Shiratori Pharmaceuticals"],"award-info":[{"award-number":["Shiratori Pharmaceuticals"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"DOI":"10.1186\/s41181-025-00404-0","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T07:05:09Z","timestamp":1762844709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nonclinical investigations of a novel heart-type fatty acid\u2013binding protein ligand, [18F]LUF: three-lot process validation, safety assessment, and radiation dosimetry"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4721-405X","authenticated-orcid":false,"given":"Jun","family":"Toyohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneyuki","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Tago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Komoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"8","key":"404_CR1","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1096\/fasebj.13.8.805","volume":"13","author":"B Binas","year":"1999","unstructured":"Binas B, Danneberg H, McWhir J, Mullins L, Clark AJ. Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization. FASEB J. 1999;13(8):805\u201312.","journal-title":"FASEB J"},{"issue":"3","key":"404_CR2","first-page":"247","volume":"16","author":"M Blau","year":"1975","unstructured":"Blau M. Letter: Radiation dosimetry of 131-I-19-iodocholesterol: the pitfalls of using tissue concentration data. J Nucl Med. 1975;16(3):247\u20139.","journal-title":"J Nucl Med"},{"key":"404_CR3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.brainres.2018.11.036","volume":"1707","author":"A Cheng","year":"2019","unstructured":"Cheng A, Shinoda Y, Yamamoto T, Miyachi H, Fukunaga K. Development of FABP3 ligands that inhibit arachidonic acid-induced \u03b1-synuclein oligomerization. Brain Res. 2019;1707:190\u20137.","journal-title":"Brain Res"},{"issue":"6","key":"404_CR4","doi-asserted-by":"publisher","first-page":"986","DOI":"10.2967\/jnumed.125.269885","volume":"66","author":"M Dakanali","year":"2025","unstructured":"Dakanali M, Zigler SS, Schwarz SW, Nickels ML, Oyama R, VanBrocklin HF, et al. FDA reconsider rules around radiation dosimetry for first-in-human studies of investigational PET radiopharmaceuticals. J Nucl Med. 2025;66(6):986\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"404_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41181-024-00245-3","volume":"9","author":"P Dillemuth","year":"2024","unstructured":"Dillemuth P, Karskela T, Ayo A, Ponkamo J, Kunnas J, Rajander J, et al. Radiosynthesis, structural identification and in vitro tissue binding study of [18F]FNA-S-ACooP, a novel radiopeptide for targeted PET imaging of fatty acid binding protein 3. EJNMMI Radiopharm Chem. 2024a;9(1):16.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"8","key":"404_CR6","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1021\/acs.molpharmaceut.4c00546","volume":"21","author":"P Dillemuth","year":"2024","unstructured":"Dillemuth P, L\u00f6vdahl P, Karskela T, Ayo A, Ponkamo J, Liljenb\u00e4ck H, et al. Switching the chemoselectivity in the preparation of [18F]FNA-N-CooP, a free thiol-containing peptide for targeted positron emission tomography imaging of fatty acid binding protein 3. Mol Pharm. 2024b;21(8):4147\u201356.","journal-title":"Mol Pharm"},{"key":"404_CR7","unstructured":"EDQM, European Directorate for the Quality of Medicines and HealthCare. Tetrabutylammonium in radiopharmaceutical preparations. The European Pharmacoepia 10.5 edition. 2021;5661."},{"issue":"1","key":"404_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.17996\/anc.21-00146","volume":"8","author":"K Fukushima","year":"2022","unstructured":"Fukushima K, Momose M, Kanaya K, Kaimoto Y, Higuchi T, Yamamoto A, et al. Imaging of heart type fatty acid binding protein under acute reperfusion ischemia using radio-labeled antibody in rat heart model. Ann Nucl Cardiol. 2022;8(1):14\u201320.","journal-title":"Ann Nucl Cardiol"},{"key":"404_CR9","doi-asserted-by":"publisher","first-page":"102547","DOI":"10.1016\/j.redox.2022.102547","volume":"59","author":"Q Guo","year":"2023","unstructured":"Guo Q, Kawahata I, Cheng A, Wang H, Jia W, Yoshino H, et al. Fatty acid-binding proteins 3 and 5 are involved in the initiation of mitochondrial damage in ischemic neurons. Redox Biol. 2023;59:102547.","journal-title":"Redox Biol"},{"key":"404_CR10","unstructured":"ICH, International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential Questiona and Answers. 2022; Memorandum. https:\/\/www.pmda.go.jp\/files\/000247624.pdf Accessed 22 Jul 2022."},{"issue":"5","key":"404_CR11","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s12149-021-01601-y","volume":"35","author":"M Kawano","year":"2021","unstructured":"Kawano M, Tsuchiya J, Bae H, Kimura K, Yokoyama K, Takahashi M, et al. Phase I clinical study of NMB58, a novel positron emission tomography (PET)-myocardial perfusion imaging tracer, conducted to evaluate its safety and pharmacokinetics in Japanese healthy adult males. Ann Nucl Med. 2021;35(5):580\u20138.","journal-title":"Ann Nucl Med"},{"issue":"1","key":"404_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-016-0004-6","volume":"1","author":"J Koziorowski","year":"2017","unstructured":"Koziorowski J, Behe M, Decristoforo C, Ballinger J, Elsinga P, Ferrari V, et al. Position paper on requirements for toxicological studies in the specific case of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2017;1(1):1.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"9","key":"404_CR13","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.2967\/jnumed.111.092528","volume":"52","author":"J Maddahi","year":"2011","unstructured":"Maddahi J, Czernin J, Lazewatsky J, Huang S-C, Dahlbom M, Schelbert H, et al. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med. 2011;52(9):1490\u20138.","journal-title":"J Nucl Med"},{"key":"404_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cca.2017.09.007","volume":"474","author":"Y Otaki","year":"2017","unstructured":"Otaki Y, Watanabe T, Kubota I. Heart-type fatty acid-binding protein in cardiovascular disease: a systemic review. Clin Chim Acta. 2017;474:44\u201353.","journal-title":"Clin Chim Acta"},{"key":"404_CR16","unstructured":"PMDA, Pharmaceuticals and Medical Device Agency. ICH-M3(R2). Guidance on Nonclinical Safety Studies for the Human Clinical Trials and Marketing Authorization for Pharmaceuticals. 2010; Yakushoku-shinsa No. 0219\u20134. https:\/\/www.pmda.go.jp\/files\/000269917.pdf Accessed 19 Feb 2010."},{"key":"404_CR17","unstructured":"PMDA, Pharmaceuticals and Medical Device Agency. ICH-S2(R1). Guidance of Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use. 2012; Yakushoku-shinsa No. 0920\u20131. https:\/\/www.pmda.go.jp\/files\/000155984.pdf Accessed 20 Sep 2012."},{"key":"404_CR15","unstructured":"PMDA, Pharmaceuticals and Medical Device Agency. The Japanese Pharmacoepia 18th edition. 2021; Notification No. 220. https:\/\/www.mhlw.go.jp\/content\/11120000\/000945683.pdf Accessed 7 Jun 2021."},{"issue":"4","key":"404_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jphs.2020.05.005","volume":"143","author":"Y Shinoda","year":"2020","unstructured":"Shinoda Y, Wang Y, Yamamoto T, Miyachi H, Fukunaga K. Analysis of binding affinity and docking of novel fatty acid-binding protein (FABP) ligands. J Pharmacol Sci. 2020;143(4):264\u201371.","journal-title":"J Pharmacol Sci"},{"issue":"4","key":"404_CR19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2967\/jnumed.119.233288","volume":"61","author":"S Srinivasan","year":"2020","unstructured":"Srinivasan S, Crandall JP, Gajwanti P, Sgouros G, Mena E, Lodge MA, et al. Human radiation dosimetry for orally and intravenously administered 18F-FDG. J Nucl Med. 2020;61(4):613\u20139.","journal-title":"J Nucl Med"},{"issue":"6","key":"404_CR20","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023\u20137.","journal-title":"J Nucl Med"},{"key":"404_CR21","unstructured":"ICRP. The 2007 recommendations of the international commission on radiological protection. ICRP publication 103. Ann ICRP. 2007;37(2\u20134):1\u2013332."},{"issue":"1","key":"404_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13550-024-01175-6","volume":"14","author":"J Toyohara","year":"2024","unstructured":"Toyohara J, Komoda T, Tago T, Ito M, Yoshino H. Light up heart-type fatty acid binding protein (FABP3) with a novel fluorine-18 labelled selective FABP3 ligand. EJNMMI Res. 2024;14(1):107.","journal-title":"EJNMMI Res"},{"issue":"10","key":"404_CR23","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1161\/01.CIR.92.10.2848","volume":"92","author":"FA Van Nieuwenhoven","year":"1995","unstructured":"Van Nieuwenhoven FA, Kleine AH, Wodzig WH, Hermens WT, Kragten HA, Maessen JG, et al. Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid-binding protein. Circulation. 1995;92(10):2848\u201354.","journal-title":"Circulation"},{"issue":"1","key":"404_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jphs.2023.02.008","volume":"152","author":"H Wang","year":"2023","unstructured":"Wang H, Fukunaga K, Cheng A, Wang Y, Arimura N, Yoshino H, et al. Novel FABP3 ligand, HY-11-9, ameliorates neuropathological deficits in MPTP-induced Parkinsonism in mice. J Pharmacol Sci. 2023;152(1):30\u20138.","journal-title":"J Pharmacol Sci"},{"key":"404_CR25","unstructured":"Yoshino H, Komoda T, Ito M, Fukunaga K, Kawahata I. Triphenylazole compound. WO\/2024\/063147 A1. 23 2024."},{"issue":"11","key":"404_CR26","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00259-013-2512-x","volume":"40","author":"P Zanotti-Fregonara","year":"2013","unstructured":"Zanotti-Fregonara P, Lammertsma AA, Innis RB. Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies. Eur J Nucl Med Mol Imaging. 2013;40(11):1781\u20133.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00404-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-025-00404-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00404-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T07:05:12Z","timestamp":1762844712000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-025-00404-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1186\/s41181-025-00404-0","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All applicable institutional and\/or national guidelines for the care and use of animals were followed, and the study protocol was approved by the institutional Research Ethics Board of Tokyo Metropolitan Institute for Geriatrics and Gerontology (approval no. 25003) and Nihon Bioresearch (approval no. 430307).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JT is an associate editor of EJNMMI Radiopharmacy and Chemistry. MI, TK, and HY are employed by Shiratori Pharmaceuticals. JT, MI, TK, and HY have a pending patent application related to this work. The other authors declare that they have no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}